Abstract
Fifty patients with non resectable and/or inoperable bronchogenic carcinoma were entered into a feasibility study of cisplatin (CDDP) given in continuous infusion with concurrent radiation therapy. The radiation therapy regimen consisted of 2 Gy given 5 days a week in the first 3 and last 2 weeks of a 7‐week split course (50 Gy of total dose). The CDDP (daily dose of 4 to 6 mg/m2) was administered to cover the days of radiation treatment by means of a central venous catheter and a portable pump. Less than 1% of predicted duration of infusion was lost due to complications related to venous access and pump. Toxicity was moderate. The overall probability of a locoregional major response (complete + partial) within 1 month after treatment completion was 86%. Twenty‐three patients underwent resection. The 1‐year actuarial probability of survival was 64%. The high response and survival rates warrant further studies on concurrent CDDP continuous infusion and radiation therapy in inoperable lung carcinoma. Copyright © 1991 American Cancer Society
Cite
CITATION STYLE
Bedini, A. V., Tavecchio, L., Milani, F., Gramaglia, A., Spreafico, C., Marchianò, A., & Ravasi, G. (1991). Prolonged venous infusion of cisplatin and concurrent radiation therapy for lung carcinoma. A feasibility study. Cancer, 67(2), 357–362. https://doi.org/10.1002/1097-0142(19910115)67:2<357::AID-CNCR2820670207>3.0.CO;2-9
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.